Use and risks of phosphorus-32 in the treatment of polycythaemia vera

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 10, 2003, Pages 1413-1417

  Parmentier, Claude ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Phosphorus 32; Polycythaemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; IMATINIB; PHOSPHORUS 32; PIPOBROMAN;

ACUTE LEUKEMIA; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG USE; HUMAN; PHLEBOTOMY; POLYCYTHEMIA VERA; REVIEW; RISK ASSESSMENT;

AGE DISTRIBUTION; AGED; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; LEUKEMIA; MALE; NEOPLASMS; PHOSPHORUS RADIOISOTOPES; PHYSICIAN'S PRACTICE PATTERNS; POLYCYTHEMIA VERA; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 0141996510     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1270-6     Document Type: Review

References (43)

1. Vaquez MH. Concerning a special form of cyanosis with accompanying excessive persistent polycythaemia. Compt Rend Soc Biol 1892; 44:384-388.
2. Osler W. Chronic cyanosis with polycythaemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 126:187-201.
3. Lawrence JH. Polycythaemia physiology, diagnosis and treatment. New York: Grune and Stratton, 1955.
4. Lawrence JH, Winchell HS, Donald WG. Leukaemia in polycythaemia vera. Ann Intern Med 1969; 70:763-771.
5. Silberstein EB. The treatment of painful osseous metastases with phosphorus 32 labeled phosphates. Semin Oncol 1993; 20 Suppl 2:10-21.
6. 32P. Br J Radiol 1976; 49:133-140.
7. Seltzer RA, Kereiakes JG, Saengerpe L. Radiation exposure from radioisotopes on pediatrics. N Engl J Med 1964; 271:84-90.
8. Mays CW. Cancer induction in man from internal radioactivity. Health Phys 1973; 25:585-592.
9. International Commission On Radiological Protection. Protection of the patient in radionuclide investigations. ICPR Publication No. 17, p 64. Oxford: Pergamon Press, 1971.
10. Berglund S., Zettervall O. (1992). Incidence of Polycythaemia vera in a defined population. Eur. J. Hematol, 48, 20-26.
11. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythaemia vera: stem cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913-916.
12. Fialkow PJ. Clonal and stem cell origin of blood cell neoplasms. In: Lobue J, Gordon AS, Silber S, eds. Contemporary hematology oncology, vol 1. New York: Plenum; 1980: 1.
13. Videbaek A. Polycythaemia vera. Acta Med Scand 1950; 138:179-187.
14. Halnan KE, Russel MH. Comparison of survival and causes of death in patients managed with and without radiotherapy. Lancet 1965; 2:760.
15. Fauvert R, Boivin P, Mallarmé J. Conduite et résultats du traitement des polyglobulies par le phosphore 32. Nouv Rev Fr Hematol 1961; 1:459-467.
16. 32P treated patients with polycythemia vera and chronic lymphocytic leukaemia. J Lab Clin Med 1964; 64:560.
17. Modan B, Lilienfeld AM. Polycythaemia vera and leukaemia: the role of radiation treatment. A study of 1222 patients. Medicine 1965; 44:305-344.
18. Szur L, Lewis SM. Hematological complications of polycythaemia vera and treatment with radioactive phosphorus. Br J Radiol 1966; 39:122-130.
19. Harman JB, Ledlie EM. Survival of polycythaemia vera patients treated with radioactive phosphorus. Br Med J 1967; 2:146.
20. Tubiana M, Attie E, Parmentier C. Le devenir des polyglobulies essentielles traitées par le phosphore radioactif à propos d'une série de 330 malades suivis pendant 12 à 24 ans. Nouv Press Med 1975; 4:1781-1786.
21. Landaw SA. Acute leukaemia in polycythaemia vera. Semin Hematol 1976; 13:33-48.
22. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythaemia vera bases on polycythaemia vera study group protocols. Semin Hematol 1986; 23:132-143.
23. Najean Y, Deschamps A, Dresch C, Daniel MT, Rain JD, Arragol JP. Acute leukaemia and myelodysplasia in polycythaemia vera. A clinical study with long-term follow-up. Cancer 1988; 61:89-95.
24. 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Leuk Lymphoma 1996; 22 Suppl 1:111-119.
25. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Group. Br J Haematol 1994; 86:233-235.
26. Tefferi A. Polycythaemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003; 78:174-194.
27. 32P (based on a series of 296 patients). Blood 1968; 32:536-548.
28. Charbord P, Caillou B, Lafleur M, Parmentier C. L'érythropoï èse inefficace au cours des splénomégalies myéloïdes: tests au Fer 59. données histologiques et cytologiques médullaires. Nouv Rev Fr Hematol 1978; 20:443-453.
29. Parmentier C, Morardet N, Gardet P, Droz JP, Charbord P, Caillou B. Granulocytic progenitor cells (CRC) cultured from patients with polycythaemia vera. Nouv Rev Fr Hematol 1980; 22:339-355.
30. Parmentier C, Charbord P, Tubiana M. L'avenir lointain de la maladie de Vaquez. Rev Prat 1981; 31:1533-1544.
31. Von Heilman E, Köhler T. Polycythaemia vera. Fortschr Med 1978; 96:941-944.
32. "Leukemia and Hematosarcoma" Cooperative Group, European Organisation for Research on Treatment of Cancer (E.O.R.T.C.). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomised trial. Br J Cancer 1981; 44:75-80.
33. Brodsky I. Busulphan treatment of polycythaemia vera. J Hematol 1974; 52:1-6.
34. Nand S, Stock W, Godwin J, Fisher SG. Leukaemogenic risk of hydroxyurea therapy in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52:42-46.
35. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythaemia Vera Study Group report on hydroxyurea in patients with polycythaemia vera. Semin Hematol 1997; 34:17.
36. Tatarsky I, Sharon R. Management of polycythaemia vera with hydroxyurea. Semin Hematol 1997; 34:24.
37. Najean Y, Rain JD, for the French Polycythaemia Study Group. Treatment of polycythaemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90:33-70.
38. Jones CM, Dickinson TM. Polycythaemia vera responds to imatinib mesylate. Am J Med Sci 2003; 325:149-152.
39. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythaemia Vera Study Group: a survey of American Society of Hematology members practice patterns. Blood 2002; 99:1144-1149.
40. Brandt L, Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Hematol 1995; 54:21-26.
41. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Green AR, Huntly BJ, Nacheva EP, Barbui T, Finazzi G. A polycythaemia vera update: diagnosis, pathobiology and treatment. Hematology (Am Soc Hematol Educ Program) 2000; 51-68.
42. Conférence de consensus. Diagnostic, Pronostic, Traitement et Surveillance des Polyglobulies. Société Française d'Hématologie, 1993.
43. Spivak JL. The optimal management of polycythemia vera. Br J Hematol 2002; 116:243-254.